PharmaCyte Biotech Inc (OTCQB:PMCB) had a tough morning trading session on December 30, declining more than most other peers in the directory of approximately 200 stocks we track in the cannabis industry with a slide of 6.0%. After closing the previous session at $0.15, shares of PMCB opened this morning at 0.15 and are trading at $0.141 at the lunch break. So far, about 2.41 million shares have changed hands, compared to an average 30-day volume of 9.52 million for PharmaCyte Biotech Inc. Shares moved as high at $0.1534 and as low as $0.135 in AM trading action.
The share depreciation gives the company a market capitalization of $127.49 million based upon 849.9 million shares outstanding.
In the past 52 weeks, shares of PharmaCyte Biotech Inc have traded as low as $0.023 and as high as $0.1689. Technical traders will take note that at $0.141, shares of PMCB are trading above their 50-day moving average (MA) at $0.075 and above their 200-day MA at $0.059. Technical analysts pay close attention to these key moving averages because they often serve as technical support and resistance levels and because a move beneath them is typically regarded as bearish.
Who is PMCB?
PharmaCyte Biotech Inc is clinical stage biotechnology company. It is engaged in developing and preparing commercialize treatments for cancer and diabetes based on proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The company is led by its CEO Kenneth L. Waggoner from its headquarters in Silver Spring, MD.
For more information on PMCB and other companies focused on the expanding legal cannabis and medical marijuana industries or to considered for contributing content, visit PotNetwork.com today.
All data provided by QuoteMedia and was accurate as of 12:00PM ET.
PPotNetwork.com is a leading publisher of market news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the legal cannabis and medical marijuana markets. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts interested in all segments, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications and market exposure. A complete disclaimer can be viewed here.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of PotNetwork.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://potnetwork.com/legal-disclaimer/.